Drug Approval | July 20, 2022
Brii Bio inks partnership with China Resources Pharmaceutical to advance the commercialization of Long-acting COVID-19 neutralizing antibody therapy
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
